Immunomedics, Inc. (IMMU) Ranks 4th In The Patent Board Biotechnology Industry Scorecard
2/5/2014 9:32:51 AM
MORRIS PLAINS, N.J., Feb. 4, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that the Company is the #4 innovator in the biotechnology industry, according to the scorecard published by the Wall Street Journal Online on WSJ.com, for the 13-week period ending January 31, 2014. The ranking is based on the scale, quality, impact and nearness to core science of the Company's patent-based intellectual property, factoring in both qualitative and quantitative aspects of the patent portfolio.
Help employers find you! Check out all the jobs and post your resume.
comments powered by